Japanese encephalitis vaccine - sanofi pasteur

Drug Profile

Japanese encephalitis vaccine - sanofi pasteur

Alternative Names: ChimeriVax-JE; Imojev; JE-CV; Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®); Single-dose Japanese encephalitis vaccine - sanofi pasteur

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Acambis
  • Developer Sanofi Pasteur
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Japanese encephalitis

Most Recent Events

  • 12 Oct 2016 Launched for Japanese encephalitis (Prevention) in South Korea (SC) prior to October 2016
  • 30 Jun 2016 Sanofi pasteur completes a phase III clinical trial in Japanese encephalitis (Prevention, In infants, In children, In adolescents, In adults) in Vietnam (SC) (NCT02492165)
  • 01 Nov 2013 Sanofi pasteur initiates enrolment in a phase IV post-approval trial in Japanese encephalitis (prevention, in children aged 1-4 years) in Thailand (NCT01981967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top